Dana-Farber Cancer Institute Inc. has divulged proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN) binding moiety covalently linked to a histone-lysine N-methyltransferase, H3 lysine-79 specific (DOT1L) targeting moiety via linker reported to be useful for the treatment of cancer.
Gluetacs Therapeutics (Shanghai) Co. Ltd. has synthesized compounds targeting protein cereblon (CRBN) and their PROTACs (proteolysis targeting chimeras) reported to be useful for the treatment of cancer, anemia, transplant rejection, neurodegeneration, infections, autoimmune, inflammatory and metabolic disorders, among others.
Researchers from Fundacio Privada Instituto de Salud Global Barcelona (ISGLOBAL), Institut de Bioenginyeria de Catalunya (IBEC) and Universitat de Barcelona have described compounds reported to be useful for the treatment of malaria.
Azura Ophthalmics Ltd. has divulged codrugs consisting of an immunomodulator moiety and a keratolytic agent reported to be useful for the treatment of eye and dermatological disorders.
Lhotse Bio Inc. has identified lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer and fibrosis, among others.
Chiesi Farmaceutici SpA has synthesized pyrrolidine derivatives acting as discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis and idiopathic pulmonary fibrosis (IPF).
Researchers at Voronoi Bio Inc. and Voronoi Inc. have disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, inflammatory bowel disease, psoriasis, rheumatoid arthritis, myocardial infarction, Alzheimer's disease, asthma and type 1 diabetes, among others.
RSS